Sacubitril Valsartan 24/36 Mg, 49/51 Mg, 97/103 Mg Cipla 24/36 mg, 49/51 mg, 97/103 mg Tablets
PDF Leaflet Revision Date: 19 September 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of symptomatic heart failure in adults with systolic dysfunction.
Dosage (summary)
Starting dose: 24/26 mg twice daily; target dose: 97/103 mg twice daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- ACE inhibitors
- Aliskiren
- Potassium-sparing diuretics
Contraindications
- Hypersensitivity
- Severe renal impairment
- Severe hepatic impairment
- History of angioedema
- Bilateral renal artery stenosis
Common side effects
- Hypotension
- Hyperkalaemia
- Dizziness
- Fatigue
Counselling Points
- Monitor blood pressure regularly.
- Report any signs of angioedema immediately.
- Avoid potassium supplements.
Serious warnings
- Risk of angioedema
- Monitor renal function
- Avoid dual RAAS blockade
Important Disclaimer
The Sacubitril Valsartan 24/36 Mg, 49/51 Mg, 97/103 Mg Cipla 24/36 mg, 49/51 mg, 97/103 mg Tablets professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
